L-743,872

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidiasis, Esophageal

Conditions

Candidiasis, Esophageal, HIV Infections

Trial Timeline

โ€” โ†’ โ€”

About L-743,872

L-743,872 is a pre-clinical stage product being developed by Merck for Candidiasis, Esophageal. The current trial status is completed. This product is registered under clinical trial identifier NCT00005921. Target conditions include Candidiasis, Esophageal, HIV Infections.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (2)

NCT IDPhaseStatus
NCT00005921Pre-clinicalCompleted
NCT00005920Phase 2Terminated

Competing Products

20 competing products in Candidiasis, Esophageal

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaPhase 1
33
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
77
Micafungin + fluconazoleAstellas PharmaPhase 3
77
Micafungin (Mycamine)Astellas PharmaPhase 1
33
Fluconazole + MicafunginAstellas PharmaApproved
85
Micafungin + CaspofunginAstellas PharmaPhase 3
77
Micafungin + FluconazoleAstellas PharmaPhase 3
77
MicafunginAstellas PharmaPhase 2
52
micafungin + caspofunginAstellas PharmaPhase 3
77
micafungin + amphotericin B deoxycholateAstellas PharmaPhase 3
77
FK463Astellas PharmaPhase 2
52
Micafungin + Liposomal Amphotericin BAstellas PharmaPhase 3
77
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
77
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
77
CaspofunginMerckPhase 2
52
L-743,872MerckPhase 2
52
Caspofungin + Amphotericin B DeoxycholateMerckPhase 2
52
Caspofungin acetate + PlaceboMerckPhase 2
52
Caspofungin + Normal SalineMerckApproved
85
caspofungin acetateMerckPhase 3
77